vs
微策略（MSTR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是微策略的1.8倍（$219.9M vs $123.0M），Orthofix Medical Inc.同比增速更快（2.0% vs 1.9%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.3%）
Strategy Inc（原名为微策略）是1989年成立的美国上市企业，主营商业智能与移动软件业务，旗下产品可帮助企业分析内外部数据以支撑经营决策，还可用于移动应用开发，总部位于弗吉尼亚州泰森斯角，商业分析赛道核心竞品包括SAP等。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MSTR vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.8倍
$123.0M
营收增速更快
OFIX
高出0.1%
1.9%
两年增速更快
OFIX
近两年复合增速
3.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $123.0M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 66.1% | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 1.9% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MSTROFIX
| Q4 25 | $123.0M | $219.9M | ||
| Q3 25 | $128.7M | $205.6M | ||
| Q2 25 | $114.5M | $203.1M | ||
| Q1 25 | $111.1M | $193.6M | ||
| Q4 24 | $120.7M | $215.7M | ||
| Q3 24 | $116.1M | $196.6M | ||
| Q2 24 | $111.4M | $198.6M | ||
| Q1 24 | $115.2M | $188.6M |
净利润MSTROFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $2.8B | $-22.8M | ||
| Q2 25 | $10.0B | $-14.1M | ||
| Q1 25 | $-4.2B | $-53.1M | ||
| Q4 24 | $-670.8M | $-29.1M | ||
| Q3 24 | $-340.2M | $-27.4M | ||
| Q2 24 | $-102.6M | $-33.4M | ||
| Q1 24 | $-53.1M | $-36.0M |
毛利率MSTROFIX
| Q4 25 | 66.1% | 71.1% | ||
| Q3 25 | 70.5% | 72.2% | ||
| Q2 25 | 68.8% | 68.7% | ||
| Q1 25 | 69.4% | 62.8% | ||
| Q4 24 | 71.7% | 69.0% | ||
| Q3 24 | 70.4% | 68.7% | ||
| Q2 24 | 72.2% | 67.8% | ||
| Q1 24 | 74.0% | 67.5% |
营业利润率MSTROFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | -5331.4% | -25.2% | ||
| Q4 24 | -842.1% | -5.3% | ||
| Q3 24 | -372.7% | -9.6% | ||
| Q2 24 | -179.7% | -12.5% | ||
| Q1 24 | -176.8% | -15.6% |
净利率MSTROFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 2164.1% | -11.1% | ||
| Q2 25 | 8752.7% | -6.9% | ||
| Q1 25 | -3797.2% | -27.4% | ||
| Q4 24 | -555.8% | -13.5% | ||
| Q3 24 | -293.1% | -13.9% | ||
| Q2 24 | -92.0% | -16.8% | ||
| Q1 24 | -46.1% | -19.1% |
每股收益（稀释后）MSTROFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $8.42 | $-0.57 | ||
| Q2 25 | $32.60 | $-0.36 | ||
| Q1 25 | $-16.49 | $-1.35 | ||
| Q4 24 | $4.49 | $-0.76 | ||
| Q3 24 | $-1.72 | $-0.71 | ||
| Q2 24 | $-0.57 | $-0.88 | ||
| Q1 24 | $-0.31 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3B | $82.0M |
| 总债务越低越好 | $8.2B | — |
| 股东权益账面价值 | $44.1B | $450.0M |
| 总资产 | $61.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资MSTROFIX
| Q4 25 | $2.3B | $82.0M | ||
| Q3 25 | $54.3M | $62.9M | ||
| Q2 25 | $50.1M | $65.6M | ||
| Q1 25 | $60.3M | $58.0M | ||
| Q4 24 | $38.1M | $83.2M | ||
| Q3 24 | $46.3M | $30.1M | ||
| Q2 24 | $66.9M | $26.4M | ||
| Q1 24 | $81.3M | $27.0M |
总债务MSTROFIX
| Q4 25 | $8.2B | — | ||
| Q3 25 | $8.2B | $157.2M | ||
| Q2 25 | $8.2B | $157.0M | ||
| Q1 25 | $8.1B | $156.9M | ||
| Q4 24 | $7.2B | $157.0M | ||
| Q3 24 | $4.2B | $118.5M | ||
| Q2 24 | $3.8B | $118.0M | ||
| Q1 24 | $3.6B | $118.2M |
股东权益MSTROFIX
| Q4 25 | $44.1B | $450.0M | ||
| Q3 25 | $52.3B | $442.5M | ||
| Q2 25 | $47.5B | $458.3M | ||
| Q1 25 | $32.2B | $458.3M | ||
| Q4 24 | $18.2B | $503.1M | ||
| Q3 24 | $3.8B | $525.9M | ||
| Q2 24 | $2.8B | $546.0M | ||
| Q1 24 | $2.4B | $570.3M |
总资产MSTROFIX
| Q4 25 | $61.6B | $850.6M | ||
| Q3 25 | $73.6B | $832.6M | ||
| Q2 25 | $64.8B | $837.2M | ||
| Q1 25 | $43.9B | $823.1M | ||
| Q4 24 | $25.8B | $893.3M | ||
| Q3 24 | $8.3B | $867.9M | ||
| Q2 24 | $7.1B | $882.0M | ||
| Q1 24 | $6.4B | $906.0M |
负债/权益比MSTROFIX
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.16× | 0.36× | ||
| Q2 25 | 0.17× | 0.34× | ||
| Q1 25 | 0.25× | 0.34× | ||
| Q4 24 | 0.39× | 0.31× | ||
| Q3 24 | 1.12× | 0.23× | ||
| Q2 24 | 1.36× | 0.22× | ||
| Q1 24 | 1.48× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MSTROFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | $-8.3M | $12.4M | ||
| Q2 25 | $-34.9M | $11.6M | ||
| Q1 25 | $-2.4M | $-18.4M | ||
| Q4 24 | $-17.3M | $23.7M | ||
| Q3 24 | $-41.0M | $11.7M | ||
| Q2 24 | $-23.3M | $9.0M | ||
| Q1 24 | $28.6M | $-18.6M |
自由现金流MSTROFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | $-11.1M | $2.5M | ||
| Q2 25 | $-37.0M | $4.5M | ||
| Q1 25 | $-5.1M | $-25.1M | ||
| Q4 24 | $-17.6M | $15.2M | ||
| Q3 24 | $-41.4M | $6.3M | ||
| Q2 24 | $-24.1M | $-360.0K | ||
| Q1 24 | $27.0M | $-29.1M |
自由现金流率MSTROFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | -8.6% | 1.2% | ||
| Q2 25 | -32.3% | 2.2% | ||
| Q1 25 | -4.6% | -13.0% | ||
| Q4 24 | -14.6% | 7.0% | ||
| Q3 24 | -35.7% | 3.2% | ||
| Q2 24 | -21.6% | -0.2% | ||
| Q1 24 | 23.5% | -15.4% |
资本支出强度MSTROFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | 2.2% | 4.8% | ||
| Q2 25 | 1.8% | 3.5% | ||
| Q1 25 | 2.5% | 3.5% | ||
| Q4 24 | 0.2% | 4.0% | ||
| Q3 24 | 0.4% | 2.7% | ||
| Q2 24 | 0.6% | 4.7% | ||
| Q1 24 | 1.3% | 5.6% |
现金转化率MSTROFIX
| Q4 25 | — | — | ||
| Q3 25 | -0.00× | — | ||
| Q2 25 | -0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MSTR
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
